Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    biocurrent
Previous Study | Return to List | Next Study

BioCurrent Electrical Stimulation for the Treatment of Dry ARMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02699216
Recruitment Status : Withdrawn
First Posted : March 4, 2016
Last Update Posted : June 6, 2018
Sponsor:
Information provided by (Responsible Party):
DuBois Vision Clinic

Brief Summary:
This study evaluates the treatment of Dry Macular Degeneration and the resulting change in vision with a very, very low current that is similar to what occurs in the body naturally. In Phase 1, 16 participants will be treated, with half receiving treatment and half a sham (no treatment). After the treatment period of one week, those not treated will be treated. In Phase 2, all participants will be treated.

Condition or disease Intervention/treatment Phase
Dry Macular Degeneration Device: Electrical Stimulation of the Retina Not Applicable

Detailed Description:
The study will assess the effectiveness of transpalpebral micro-current electrical stimulation on improving the visual acuity in subjects with vision loss from Dry Macular Degeneration. The BioCurrent electrical stimulation will be applied by a device with the intended use of treating Dry Macular Degeneration. The device delivers a micro-current, an electrical current in the one millionth of an ampere range, to the retina in frequencies changing in a pre-defined pattern from 5Hz to 80Hz during each spot (40 sec). The device also incorporates a voltage limiter (a maximum of 245 micro A is possible) and a current level indicator. 200 micro A will be used. Very low electrical micro-current is delivered to the subject through the goggle probe.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: BioCurrent Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration
Study Start Date : January 2016
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1 Active Treatment
Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
Device: Electrical Stimulation of the Retina
Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.

Placebo Comparator: Phase 1 Sham Treatment
Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
Device: Electrical Stimulation of the Retina
Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.

Experimental: Phase 2 Open Label
Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
Device: Electrical Stimulation of the Retina
Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.




Primary Outcome Measures :
  1. Change in Best-corrected Visual Acuity using the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart [ Time Frame: Baseline, Day 5 ]
    Significant changes in ETDRS visual acuity; baseline and Day 5.


Secondary Outcome Measures :
  1. Changes in retinal sensitivity assessed by Microperimetry [ Time Frame: Baseline, Day 5 ]
    Significant Changes in retinal sensitivity; baseline and Day 5.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Best-corrected visual acuity can be no better than 20/40 and no worse than 20/200 for each enrolled eye
  • Confirmed diagnosis of Dry MD
  • Vision loss attributable to Dry MD
  • Subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent

Exclusion Criteria:

  • Any retinal pathology other than Dry MD
  • Evidence or history of wet MD
  • Previous intravitreal injection
  • Seizure disorders
  • Dense cataract
  • Eyelid pathology at the treatment sites
  • Any prior electrical micro-stimulation treatment to the eyes
  • Poor general health
  • Active cancer
  • Life expectancy less than 12 months
  • Non-ambulatory
  • Not considered suitable for participation for any other reason
Layout table for additonal information
Responsible Party: DuBois Vision Clinic
ClinicalTrials.gov Identifier: NCT02699216    
Other Study ID Numbers: WSW001
First Posted: March 4, 2016    Key Record Dates
Last Update Posted: June 6, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by DuBois Vision Clinic:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases